Hemostasis Today

May, 2026
May 2026
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Tooba Rehman: Extending Impella 5.5 Support Beyond 14 Days in Cardiogenic Shock
Mar 27, 2026, 14:53

Tooba Rehman: Extending Impella 5.5 Support Beyond 14 Days in Cardiogenic Shock

Tooba Rehman, Medical Doctor, shared a post on LinkedIn about a recent article she and her colleagues co-authored, adding:

Delighted to share my latest publication:

Impact of Impella 5.5 Duration Support and Clinical Outcomes in Cardiogenic Shock: A Systematic Review and Meta-Analysis

Cardiogenic shock remains one of the most challenging conditions we manage, and optimizing mechanical circulatory support strategies is critical.

In our latest meta-analysis (1,440 patients across 5 studies), we explored whether extending Impella 5.5 support beyond 14 days offers meaningful clinical benefits.

Grateful to my Amazing Team!”

Title: Impact of Impella 5.5 Duration Support and Clinical Outcomes in Cardiogenic Shock: Evidence from a Systematic Review and Meta-Analysis of Observational Studies

Authors: Mrunalini Dandamudi, Srinivas Vunnamb, Tooba Rehman, Muhammad Aqib Faizan, Miguel A Samaniego-Laguna, John Cedric Mojica, Juliana Giorgi

 

Read the Full Article on  JHTL OPEN

Tooba Rehman: Extending Impella 5.5 Support Beyond 14 Days in Cardiogenic Shock

Muhammad Aqib Faizan, Clinical Intern at District Headquarter Hospital, MTI, DIKhan, shared this post, adding:

“Significantly higher risk of implant-site hematoma and infection necessitates meticulous vascular management, infection-prevention strategies and close clinical surveillance.”

Stay updated with Hemostasis Today.